REFERENCES
- Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359(17):1811–1821.
- Cardona F, Rojo-Martínez G, de la Cruz Almaraz M, Soriguer F, García-Fuentes E, Tinahones FJ. Uric acid predicts type 2 diabetes mellitus in the general population. Endocrinol Nutr 2009;56(2):66–70.
- Kodama S, Saito K, Yachi Y, The association between serum uric acid and development of type 2 diabetes mellitus. A Meta-Analysis. Diabetes Care 2009;32(9):1737–1742.
- Kramer CK, von Mühlen D, Jassal SK, Barrett-Connor E. Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study. Diabetes Care 2009;32(7):1272–1273.
- Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 2004;26(2):177–190.
- Furnsinn C, Waldhausl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia 2002;45(9):1211–1223.
- Fujiwara T, Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci 2000;67(20):2405–2416.
- Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10(4):355–361.
- Campbell IW. Long-term glycemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004;58(2):192–200.
- Dormandy JA, Charbonnel B, Eckland DJ, PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366(9493):1279–1289.
- Tominaga M. Diagnostic criteria for diabetes mellitus. Rinsho Byori 1999;47(10):901–908.
- Ma Y, Olendzki BC, Merriam PA, A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes. Nutrition 2008;24(1):45–56.
- Tominaga M, Makino H, Yoshino G, Japanese standard reference material JDS Lot 2 for haemoglobin A1c. II: present state of standardization of haemoglobin A1c in Japan using the new reference material in routine clinical assays. Ann Clin Biochem 2005;42(Pt 1):47–50.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412–419.
- Gotfredsen A, McNair P, Christiansen C, Transbol I. Renal hypouricaemia in insulin treated diabetes mellitus. Clin Chim Acta 1982;120(3):355–361.
- Cook DG, Shaper AG, Thelle DS, Whitehead TP. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J 1986;62(733):1001–1006.
- Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008–3011.
- Riches PL, Wright AF, Ralston SH. Recent insights into the pathogenesis of hyperuricaemia and gout. Hum Mol Genet 2009;18(R2):R177–R184.
- Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78(11):6858–6862.
- Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med 1993;14(6):615–631.
- Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res 2003;44(3):512–521.
- So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010;120(6):1791–1799.
- Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial. Endocrine 2012;41(3):435–441.
- Nissen SE. The rise and fall of rosiglitazone. Eur Heart J 2010;31(7):773–776.
- Bakker SJ, Gans RO, ter Maaten JC, Teerlink T, Westerhoff HV, Heine RJ. The potential role of adenosine in the pathophysiology of the insulin resistance syndrome. Atherosclerosis 2001;155(2):283–290.